Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients

Seropositivity for anti-citrullinated peptide antibodies (ACPA) in patients with rheumatoid arthritis (RA), a chronic autoimmune arthritis, is associated with worse long-term disease outcomes. ACPA is ubiquitously tested in RA patients, but other autoantibodies exist (in both citrullinated and non-c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The pharmacogenomics journal 2020-06, Vol.20 (3), p.516-523
Hauptverfasser:	Ling, Stephanie F., Nair, Nisha, Verstappen, Suzanne M. M., Barton, Anne, Zucht, Hans-Dieter, Budde, Petra, Schulz-Knappe, Peter, Plant, Darren
Format:	Artikel
Sprache:	eng
Schlagworte:	45 631/114/2413 692/53/2423 82 82/79 Adalimumab Adalimumab - therapeutic use Adult Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - epidemiology Arthritis, Rheumatoid - genetics Artificial insemination Autoantibodies Autoantibodies - genetics Biomedical and Life Sciences Biomedicine Citrulline Cohort Studies Development and progression Drug metabolism Drug therapy Female Gene Expression Genetic aspects Germany - epidemiology Human Genetics Humans Immunotherapy Male Methotrexate Methotrexate - therapeutic use Middle Aged Monoclonal antibodies Oncology Patient outcomes Pharmacotherapy Predictive Value of Tests Prospective Studies Proteomics - methods Psychopharmacology Rheumatoid arthritis TNF inhibitors Treatment Outcome United Kingdom - epidemiology Vimentin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!